Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation|
|Author:||Costa Araujo, Priscila Pereira|
Marcello, Marjory Alana
Tincani, Alfio Jose
Trindade Guilhen, Ana Carolina
Morari, Elaine Cristina
Ward, Laura Sterian
|Abstract:||Literature has consistently shown associations of BRAFV600E mutation with papillary thyroid cancer clinical features. However, the clinical utility of BRAF expression has not been clinically explored so far. We studied 67 thyroid nodules (32 benign nodules and 35 PTC cases). BRAF mRNA expression levels measured by a quantitative real-time PCR and a PCR-RFLP were used to identify BRAFV600E mutation. BRAF mRNA expression was significantly higher in malignant (198.2 +/- 373.9 AU) than in benign (4.1 +/- 6.9 AU) nodules (p < 0.0001). BRAF expression identified malignancy with a sensitivity of 80.6%, specificity of 77.1%, positive predictive value of 75.8%, and negative predictive value of 81.8%. A cut-point of 4.712, identified by the ROC curve, was able to sort out malignant nodules with an accuracy of 78.8%. Although we did not find any correlation between the presence of BRAF V600E mutation and clinical or tumor features such as age (p = 0.309), gender (p = 0.5453), ethnicity (p = 0.9820), tumor size (p = 1.000), multifocality (p = 0.2530) or mRNA levels (p = 0.7510), the study power for BRAF expression and diagnosis (99%; FPRP = 0.85) indicated that data is noteworthy despite the relative small number of patients investigated. We concluded that BRAF mRNA expression may help to identify PTC among thyroid nodules independently of the presence of BRAFV600E mutation. (C) 2012 Elsevier GmbH. All rights reserved.|
|Subject:||Papillary thyroid cancer|
|Appears in Collections:||FCM - Artigos e Materiais de Revistas Científicas|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.